All articles tagged with #ultragenyx
The FDA has approved Fayuvi, a one-time gene therapy from Ultragenyx, as the first treatment for Sanfilippo syndrome type A. The therapy, priced at $3.95 million, addresses the underlying genetic cause of the neurodegenerative disorder, offering hope to families previously left with only symptom management.
Ultragenyx reported that its experimental Angelman syndrome drug, apazunersen (GTX-102), failed its Phase 3 trial, missing both primary and secondary endpoints. The setback caused shares to plunge 43% and prompted the company to seek significant expense reductions. This failure undermines Ultragenyx’s path to profitability, as the drug was expected to be a major revenue driver, while the company continues to pursue approvals for other gene therapies.
Ultragenyx’s experimental drug apazunersen failed to show benefit over a sham treatment in a Phase 3 trial for Angelman syndrome, causing its stock to drop 43%. The company is now reviewing the program’s future and planning significant expense reductions, while analysts downgrade the stock due to the loss of a key profitability driver.
Shares of Ultragenyx and Mereo BioPharma plummeted after their Phase 3 trial for the brittle-bone disease treatment setrusumab failed to meet primary endpoints, despite secondary improvements in bone density, leading to significant market value losses and cautious outlooks from analysts.
Ultragenyx Pharmaceutical's experimental drug setrusumab for osteogenesis imperfecta failed to reduce fracture rates in late-stage studies, leading to a 43.5% drop in its stock price and potential discontinuation of the program, despite improvements in bone mineral density.
Ultragenyx and Mereo's late-stage clinical trial for a rare bone disease drug has failed, marking a significant setback for the development program.
The FDA has declined to approve Ultragenyx's gene therapy, highlighting ongoing challenges in biotech approvals, while other news includes AstraZeneca's promising hypertension drug and insights into FDA commissioner Marty Makary's initiatives.